IGF-1 LR3 vs BPC-157
Side-by-side comparison of IGF-1 LR3 and BPC-157: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
IGF-1 LR3
BPC-157
IGF-1 LR3
IGF-1 LR3 (Long R3 IGF-1) is a synthetic analog of human insulin-like growth factor 1 modified at two positions to dramatically extend its serum half-life and amplify its tissue bioactivity compared to native IGF-1. The…
Lowest listed price: $49.99 across 4 listings
Full IGF-1 LR3 profileBPC-157
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of human gastric juice…
Lowest listed price: $34.99 across 15 listings
Full BPC-157 profileSide-by-side comparison
| Attribute | IGF-1 LR3 | BPC-157 |
|---|---|---|
| Category | Growth Hormone / IGF-1 Axis | Injury, Repair & Recovery |
| Research Stage | Preclinical | Preclinical |
| Mechanism of Action | IGF-1 Receptor Signaling IGF-1 LR3 binds the IGF-1 receptor (IGF1R) - a transmembrane receptor tyrosine kinase expressed on virtually every cell type in the human body. IGF1R activation triggers two principal intracellular signaling cascades: PI3K / Akt / mTOR… | Nitric Oxide (NO) System Modulation BPC-157 exerts a central integrative effect through modulation of the nitric oxide system. Studies by Seiwerth et al. (2022) demonstrated that BPC-157 counteracts both NO-excess and NO-deficiency states, functioning as a… |
| Half-Life | 20-30 hours (community/vendor estimate; no published human PK study of IGF-1 LR3) vs ~12 minutes for native IGF-1 | Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived. |
| Typical Dose Range | 20-80 mcg per day | 200-500 mcg subcutaneous 1-2x daily (community protocols); 1-10 mcg/kg in animal studies |
| Dosing Frequency | Once daily, typically post-workout or in the morning | Twice daily (AM and PM) for optimal serum levels; once daily acceptable |
| Administration | Subcutaneous, Intramuscular | Subcutaneous, Oral, Intraperitoneal, Intravenous |
| Side Effects | Acute and Common - Hypoglycemia — The primary acute safety concern. Post-injection blood glucose drops can produce shakiness, sweating, confusion, palpitations, and in severe cases loss of consciousness. Mitigation: 30-40g of fast-digesting carbohydrate within… | Generally well-tolerated. Mild nausea or GI discomfort during initial use. Temporary increase in pain/inflammation at injury site (healing response). Rare: drowsiness, dizziness, mild headache. Very rare: transient changes in blood pressure. |
| Molecular Weight | 9117 Da | 1419.5 g/mol (average); molecular formula C62H98N16O22 |
| Common Vial Sizes | 100mcg, 1mg | 5mg, 10mg |
Price History
3 data points- Half Nattys
- Ion Peptide
- Disguised Alpha
Price History
7 data points- OF
- BM
- Half Nattys
- LB
- Ion Peptide
- BHG Labs
IGF-1 LR3: potential benefits
- Muscle hypertrophy
- Recovery
- Protein synthesis
- Fat metabolism
- Glucose uptake
BPC-157: potential benefits
- Accelerated tendon and ligament healing with improved biomechanical strength in preclinical soft-tissue injury models (PMID: 30915550)
- Gastric and GI mucosal cytoprotection against ethanol-induced lesions, mediated in part by the nitric oxide system (PMID: 30279308)
- Healing of cysteamine-induced colitis and colon anastomosis in preclinical inflammatory bowel disease models (PMID: 24304574)
- Neuroprotection with dopaminergic and nitric oxide-system modulation in central nervous system injury models such as stroke and dopamine-receptor blockade (PMID: 34380875)
- Promotion of angiogenesis via VEGFR2 up-regulation, internalization, and VEGFR2-Akt-eNOS signaling in rat hind-limb ischemia and endothelial assays (PMID: 27847966)
- Tendon fibroblast outgrowth, cell survival, and migration through FAK-paxillin pathway activation (PMID: 21030672)
- Growth hormone receptor up-regulation in tendon fibroblasts, potentiating growth hormone's proliferative effect (PMID: 25415472)
- Nitric oxide-system interaction with endothelium protection, angiogenesis, and EGR-1-mediated growth-factor and collagen expression (PMID: 22300085)
Frequently asked
What's the difference between IGF-1 LR3 and BPC-157?
IGF-1 LR3 is a growth hormone / igf-1 axis that igf-1 receptor signaling igf-1 lr3 binds the igf-1 receptor (igf1r) - a transmembrane receptor tyrosine kinase expressed on virtually every cell type in the human body. igf1r…. BPC-157 is a injury, repair & recovery that nitric oxide (no) system modulation bpc-157 exerts a central integrative effect through modulation of the nitric oxide system. studies by seiwerth et al. (2022) demonstrated that…. The two differ in mechanism, half-life (20-30 hours (community/vendor estimate; no published human PK study of IGF-1 LR3) vs ~12 minutes for native IGF-1 vs Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived.), and typical dose range.
Which has the longer half-life, IGF-1 LR3 or BPC-157?
IGF-1 LR3 has a half-life of 20-30 hours (community/vendor estimate; no published human PK study of IGF-1 LR3) vs ~12 minutes for native IGF-1. BPC-157 has a half-life of Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived.. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, IGF-1 LR3 or BPC-157?
Lowest listed price on BodyHackGuide: IGF-1 LR3 from $49.99, BPC-157 from $34.99. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack IGF-1 LR3 and BPC-157?
Stacking depends on mechanism overlap, safety profile, and goals. IGF-1 LR3 and BPC-157 should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy IGF-1 LR3 or BPC-157
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.